Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

Conditions: Advanced Solid Tumor; Urinary Bladder Neoplasm; Triple Negative Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Ovarian Neoplasm
Interventions: Drug: BT8009; Drug: Pembrolizumab
Sponsors: BicycleTx Limited
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 18, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments